Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this methodology study is to evaluate the effect of AZD8309 on cells and inflammatory biomarkers in nasal lavage and blood after nasal challenge with lipopolysaccharide (LPS)
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | AZD8309 |
|
| 2 | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD8309 | Drug | oral solution 30 mg/g, dose: 300mg bid for 3 days |
| |
| AZD8309 |
| Measure | Description | Time Frame |
|---|---|---|
| Neutrophil numbers in nasal lavage | 3 times each in the end of two treatment periods |
| Measure | Description | Time Frame |
|---|---|---|
| Cells and inflammatory biomarkers in nasal lavage | 3 times in the end of the two treatment periods | |
| Cells and inflammatory biomarkers in blood | 2 times in the beginning and 5 times in the end of the two treatment periods |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lars Olaf Cardell | Department of Otorhinolaryngology, Malmö University Hospital, Sweden | Principal Investigator |
| Leif Eriksson | AstraZeneca R&D Lund, Sweden | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Malmö | Sweden |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24341382 | Derived | Leaker BR, Barnes PJ, O'Connor B. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. Respir Res. 2013 Dec 16;14(1):137. doi: 10.1186/1465-9921-14-137. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C573077 | AZD8309 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
oral solution 30 mg/g, dose: 300mg bid for 3 days |
|